Introduction to HER2-Directed Tumor-Agnostic Approaches
Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC
Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.
Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC
Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.
Achieving Health Equity in Lung Cancer Surgery
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Developers Terminate Clinical Program for Ociperlimab in Lung Cancer
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.